ORYZON strengthens vafidemstat patent portfolio with U.S. Notice of Allowance

Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company and global leader in epigenetics, today announced that the United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance for its patent application US 17/439,575, entitled “Methods of treating borderline personality disorder”, further strengthening its intellectual property portfolio for vafidemstat, Oryzon’s LSD1 inhibitor in clinical development for the treatment of psychiatric disorders, including borderline personality disorder (BPD). The allowed claims cover the use of LSD1 inhibitors for the treatment of non-aggressive symptoms of BPD, complementing Oryzon’s patent portfolio in aggression. 

Once granted, the U.S. patent is expected to remain in force until at least 2040, excluding any potential patent term adjustments or extensions. Corresponding patents have been granted or allowed in Australia, Europe, Japan, Mexico, Russia, Singapore, and South Africa, with additional applications pending in other jurisdictions. 

“This U.S. Notice of Allowance reinforces our intellectual property position for vafidemstat in borderline personality disorder and supports its long-term development and commercial potential in an area of significant unmet medical need,” said Neus Virgili, Oryzon’s Chief IP Officer. 

In addition to this patent family, Oryzon holds other patents covering the use of vafidemstat for the treatment of CNS disorders, including a patent family directed to the treatment of aggression and social withdrawal, with patents granted or allowed in Australia, Canada, Europe, Hong Kong, Israel, Japan, South Korea, Malaysia, the Philippines, and Russia, and additional applications pending in other jurisdictions. These patents are expected to remain in force until at least 2038, excluding any potential patent term 
extensions.